Подписывайтесь на нас

Одна из главных задач Life4me+ — предотвращение новых случаев заражения ВИЧ-инфекцией и другими ИППП, гепатитом C и туберкулезом.

Приложение позволяет установить анонимную связь между врачами и ВИЧ-позитивными людьми, дает возможность организовать своевременный прием ваших медикаментов, получать замаскированные напоминания о них.

Назад
19 июля 2016, 23:00
68

Препарат Triumeq оказался эффективнее стандартных ЛС в терапии ВИЧ-инфекции у женщин

Препарат Triumeq оказался эффективнее стандартных ЛС в терапии ВИЧ-инфекции у женщин - изображение 1

ViiV Healthcare presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV.[1] Results show statistically superior viral suppression (HIV-1 RNA <50 c/mL) rates at week 48: 82% versus 71% (adjusted difference 10.5%, 95% CI: 3.1%-17.8%, p=0.005) respectively.1 ARIA was a non-inferiority study with a pre-specified analysis for superiority. Both non-inferiority and superiority endpoints were met, with superiority being driven by lower rates of both virological failures and discontinuations due to adverse events (AEs) in the dolutegravir/abacavir/lamivudine group.1

“Women account for over half of the almost 35 million adults living with HIV worldwide, yet unfortunately they are consistently under-represented in HIV clinical trials,” said John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare. “For this reason, we are committed to ensuring that the specific treatment needs of women are investigated. This trial not only provides physicians with important additional information about Triumeq, it also builds on the strong body of evidence supporting the efficacy of dolutegravir-based regimens in a broad range of patient populations.”

The safety profile of dolutegravir/abacavir/lamivudinewas favourable compared to ATV/r plus TDF/FTC, with fewer drug-related AEs reported on the dolutegravir/abacavir/lamivudinearm (33% vs 49%); there were also fewer AEs leading to discontinuation compared to those in the ATV/r plus TDF/FTC arm (4% vs 7%).1

Drug-related AEs reported in the dolutegravir/abacavir/lamivudinearm included, nausea (31 individuals / 13%), diarrhoea (12 / 5%), headache (5 / 2%) and dyspepsia (4 / 2%).1 In the ATV/r plus TDF/FTC group, drug-related AEs included nausea (35 / 14%), diarrhoea (18 / 7%), ocular icterus (18 / 7%), dyspepsia (15 / 6%), headache (14 / 6%) and jaundice (13 / 5%).1

There were fewer subjects meeting virologic non-response criteria (VL >50c/mL) in the dolutegravir/abacavir/lamivudinearm (6%) compared to the other group (14%) at week 48.1 Of the women that met protocol-defined virologic withdrawal criteria, none on the dolutegravir/abacavir/lamivudinearm had treatment-emergent resistance mutations to the components of dolutegravir/abacavir/lamivudine, compared with one in the comparator group.1